Double-blind, Randomized, Placebo-controlled, Single Site Study to Evaluate the Effects of Evolocumab (AMG 145) Treatment, Alone and in Combination With Atorvastatin, on Lipoprotein Kinetics

Trial Profile

Double-blind, Randomized, Placebo-controlled, Single Site Study to Evaluate the Effects of Evolocumab (AMG 145) Treatment, Alone and in Combination With Atorvastatin, on Lipoprotein Kinetics

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Atorvastatin (Primary) ; Evolocumab (Primary)
  • Indications Dyslipidaemias; Hyperlipidaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms FLOREY; PROFICIO
  • Sponsors Amgen
  • Most Recent Events

    • 30 Aug 2017 Results assessing factorial effects of Evolocumab and Atorvastatin on lipoprotein metabolism, were presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
    • 21 Aug 2017 According to an Amgen media release, data feom this trial will be presented at the European Society of Cardiology (ESC) Congress 2017.
    • 09 Dec 2016 Results assessing factorial effects of Evolocumab and Atorvastatin on lipoprotein metabolism published in the Circulation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top